CSBio CSBio

X
[{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Orphan Drug Status to RedHill\u2019s RHB-204 to Treat Nontuberculous Mycobacteria Disease","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"RedHill Biopharma"},{"orgOrder":0,"company":"Kamada","sponsor":"Israeli Health Authorities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kamada Signs a Supply Agreement with the Israeli Health Authorities for the Investigational Anti-COVID-19 Plasma-Derived Therapy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Kamada"},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kamada Announces Top-Line Results from its Phase 1\/2 Clinical Trial of its Plasma-Derived Hyperimmune Globulin (IgG) Treatment for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Kamada"},{"orgOrder":0,"company":"Israel Institute for Biological Research","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NRx Pharmaceuticals and Hungarian Health Officials Agree on Pathway for ZYESAMI\u00ae and BriLife COVID-19 Vaccine Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Israel Institute for Biological Research"},{"orgOrder":0,"company":"Stero Biotechs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Stero Biotechs Report Initial Results in the Exploratory Study it Supports of CBD-Based Treatment for Covid-19 Severe Patients","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Stero Biotechs"},{"orgOrder":0,"company":"BiomX","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","amount":"$5.0 million","upfrontCash":"Undisclosed","newsHeadline":"CFF Supporting Phase 1\/2 Trial of Phage Therapy for P. aeruginosa Infections","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Dosing of the First Two Patients in Phase 1b\/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"orgOrder":0,"company":"BiomX","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces $7.5 Million Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Positive Results from Part 1 of the Phase 1b\/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"orgOrder":0,"company":"BiomX","sponsor":"OrbiMed","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Second Closing of $7.5 Million Private Placement","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"BiomX"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Announces Completion of Patient Dosing in Part 2 of the Phase 1b\/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            BX004 is developed by utilizing company's proprietary BOLT platform, which is under phase 1/2 clinicaldevelopment for the treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

            Lead Product(s): BX004

            Therapeutic Area: Infections and Infectious Diseases Product Name: BX004

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 04, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BX004, utilizing its proprietary BOLT platform, for the treatment of CF patients with chronic pulmonary infections caused by P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

            Lead Product(s): BX004

            Therapeutic Area: Infections and Infectious Diseases Product Name: BX004

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BiomX expects to use the aggregate net proceeds to fund clinical development of BX004 for the treatment of lung infections in patients with cystic fibrosis, the development of other programs, and research activities.

            Lead Product(s): BX004

            Therapeutic Area: Infections and Infectious Diseases Product Name: BX004

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: OrbiMed

            Deal Size: $7.5 million Upfront Cash: Undisclosed

            Deal Type: Private Placement May 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BiomX expects to use the net proceeds from the PIPE to fund clinical development of BX004 for the treatment of lung infections in patients with cystic fibrosis, the development of other programs and research activities.

            Lead Product(s): BX004

            Therapeutic Area: Infections and Infectious Diseases Product Name: BX004

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: OrbiMed

            Deal Size: $7.5 million Upfront Cash: Undisclosed

            Deal Type: Private Placement February 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BX004 is active against antibiotic resistant strains of P. aeruginosa and demonstrated great biofilm penetration, an assemblage of surface-associated microbial cells enclosed in an extracellular polymeric substance the major causes for antibiotic resistance.

            Lead Product(s): BX004

            Therapeutic Area: Infections and Infectious Diseases Product Name: BX004

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BX004, a novel phage cocktail targeting P. aeruginosa, demonstrated activity against antibiotic resistant strains of P. aeruginosa, as well as enhanced biofilm penetration compared to antibiotic therapies.

            Lead Product(s): BX004

            Therapeutic Area: Infections and Infectious Diseases Product Name: BX004

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 27, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            BiomX has been given grant to support a clinical trial of BX004, a phage therapy to fight Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). In lab experiments conducted by BiomX, BX004 killed antibiotic-resistant strains of P. aeruginosa.

            Lead Product(s): BX004

            Therapeutic Area: Infections and Infectious Diseases Product Name: BX004

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Funding January 05, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus. Preclinical and phase 1/2 trials have demonstrated no safety signals of concern and have further demonstrated immunologic response.

            Lead Product(s): rVSV-SARS-CoV-2-S Vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: IIBR-100

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: NRx Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Company’s IgG product demonstrated a favorable safety profile, and there were no infusion-related reactions or adverse events considered related to study drug.

            Lead Product(s): Plasma-derived hyperimmune globulin

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Stero Biotechs reported that preliminary data from the exploratory study are encouraging. CBD has been shown to have a beneficial effect on a number of inflammatory markers that are elevated in Covid-19 patients and may have clinical merits as well.

            Lead Product(s): Cannabidiol

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 25, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY